Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call Transcript July 31, 2025Agios Pharmaceuticals, Inc. misses on earnings expectations.
Agios Pharmaceuticals Inc. (AGIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 5,767,466 | $191,825,919 | +2% | 0.83% |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,325,000 | $77,329,500 | +7% | 5.46% |
| 3. | Armistice Capital Steven Boyd | 1,168,000 | $38,847,680 | -43% | 0.67% |
| 4. | Citadel Investment Group Ken Griffin | 1,081,470 | $35,969,692 | +26% | 0.01% |
| 5. | Caligan Partners David Johnson | 1,071,258 | $35,630,041 | +53% | 6.85% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.00 | 40,322 | $1,249,982.00 | 41,722 | 2019-11-13 | Filing | |
| $31.00 | 8,064 | $249,984.00 | 97,567 | 2019-11-13 | Filing | |
| $31.00 | 403,225 | $12,499,975.00 | 1,777,824 | 2019-11-12 | Filing | |
| $83.44 | 200 | $16,688.00 | 571 | 2018-03-16 | Filing | |
| $67.00 | 851,154 | $57,027,318.00 | 1,374,599 | 2018-01-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.67 | 11,085 | $406,486.95 | 123,528 | 2025-08-08 | Filing | |
| $40.00 | 1,400 | $56,000.00 | 17,603 | 2025-07-10 | Filing | |
| $38.76 | 847 | $32,829.72 | 61,271 | 2025-07-09 | Filing | |
| $37.93 | 11,067 | $419,771.31 | 62,118 | 2025-07-09 | Filing | |
| $34.17 | 4,091 | $139,789.47 | 61,271 | 2025-07-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,682,019 | $188,983,952 | 0% | |
| 2. | 4,833,760 | $160,770,870 | 0% | |
| 3. | 3,590,150 | $119,408,389 | 2.63% | |
| 4. | 2,326,489 | $77,401,053 | 0.65% | |
| 5. | 1,951,113 | $64,894,018 | 0% |
News See All
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at TD Cowen reaffirmed their Buy rating on Agios Pharmaceuticals, Inc.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C.
10 Best Small-Cap Growth Stocks to Buy According to Analysts
On March 26, Gabelli Funds released its small-cap 2025 outlook, highlighting the valuation discounts backing the small caps and the tailwinds from the macroeconomic backdrop.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Agios’ First Quarter 2025 Conference Call. At this time all participants are in a listen-only mode. There will be a question-and-answer session at the end.
10 Best Small-Cap Stocks to Buy Before They Explode
Since the announcement of tariffs, investors have been concerned regarding the market volatility.
10 Best Small-Cap Stocks to Buy Now
The S&P 500 index has reached its all-time highs, achieving returns of over 20% for two second consecutive years post-COVID.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Agios' Fourth Quarter 2024 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
Billionaire Hedge Funds
